The company's pipeline includes TLR and TLR5 agonists for pathogen recognition and activation of innate immunity, as well as Collagenase enzymes derived from microorganisms for the treatment of musculoskeletal diseases. CONNEXT aims to expand indications to cover a wide range of diseases in oncology and dermatology, and seeks global collaborations. Founded in 2017 and based in Daegu, South Korea, CONNEXT specializes in immuno-oncology and regenerative medicine.